HRT vs Antidepressants for menopause. The honest decision.

Quick comparison at a glance

The short version — here is how Hormone Replacement Therapy (HRT) and Antidepressants for Vasomotor Symptoms stack up on the questions most patients ask before picking one.

Hormone Replacement Therapy (HRT)

• Drug class: Estrogen (typically bioidentical estradiol) plus progestogen (typically micronized progesterone) for women with an intact uterus. Estrogen alone for women post-hysterectomy.
• Brand names: Estradiol products + progesterone for women with uterus
• Mechanism: Replaces declining ovarian estradiol to directly address the hormonal cause of menopausal symptoms. Progestogen protects the uterine lining from unopposed estrogen exposure.
• Dosing: Multiple routes and doses available — oral, transdermal (patch, gel, spray), and vaginal. Dose and route matched to patient's risk profile and preferences.
• Half-life: Varies by formulation.
• FDA indication: Moderate to severe vasomotor symptoms of menopause, moderate to severe vulvovaginal atrophy, and prevention of postmenopausal osteoporosis in women at high risk.
• FDA status: FDA-approved in multiple formulations and routes.
• Manufacturer: Multiple manufacturers (brand and generic).
• Common side effects: Breast tenderness, bloating, headache, nausea (oral), mood changes, breakthrough bleeding. Elevated VTE risk with oral route; specific considerations regarding long-term use and cancer risks.
• Typical price range: Generic oral estradiol $10-30/month; transdermal patches $20-80/month; combination products vary. Often covered by insurance for menopause indications.

Antidepressants for Vasomotor Symptoms

• Drug class: SSRIs and SNRIs with evidence for vasomotor symptom reduction
• Brand names: Brisdelle (paroxetine 7.5 mg), Effexor/venlafaxine, Lexapro/escitalopram (off-label)
• Mechanism: Modulate serotonin and norepinephrine pathways in the thermoregulatory centers of the brain. The mechanism by which this reduces hot flashes is not fully understood but is well-documented in randomized trials.
• Dosing: Low-dose paroxetine (Brisdelle) 7.5 mg at bedtime is FDA-approved for vasomotor symptoms. Venlafaxine 37.5-75 mg daily, escitalopram 10-20 mg daily, and a few others are used off-label with evidence support.
• Half-life: Varies by drug — paroxetine ~21 hours, venlafaxine ~5 hours (parent compound), escitalopram ~27-32 hours.
• FDA indication: Brisdelle (low-dose paroxetine) is specifically FDA-approved for moderate-to-severe vasomotor symptoms associated with menopause. Other SSRIs and SNRIs are used off-label.
• FDA status: Brisdelle is FDA-approved for vasomotor symptoms. Other SSRIs/SNRIs are FDA-approved for depression/anxiety and used off-label for menopause.
• Manufacturer: Sebela Pharmaceuticals (Brisdelle); multiple manufacturers for other SSRIs/SNRIs.
• Common side effects: Nausea, dry mouth, sleep disturbance, sexual side effects (decreased libido, anorgasmia — especially relevant for menopause patients). Paroxetine and other SSRIs can interact with tamoxifen, which matters for breast cancer survivors.
• Typical price range: Brand Brisdelle is $50-150/month; generic paroxetine (higher dose, used off-label for hot flashes) is typically $10-30/month. Other SSRIs/SNRIs vary.

What the trials actually show

Head-to-head comparisons and placebo-controlled trials give a reasonably clear picture of the relative effectiveness of HRT vs non-hormonal options for vasomotor symptoms.

• HRT reduces hot flash frequency by roughly 75-90% and severity by similar margins in most trials. It is the most effective pharmacologic option for moderate-to-severe vasomotor symptoms.
• Paroxetine 7.5 mg (Brisdelle) reduces hot flash frequency by roughly 30-50% in placebo-controlled trials. Effectiveness is modest but real.
• Venlafaxine 75 mg reduces hot flash frequency by 50-60% in trials — one of the more effective non-hormonal options, though at a higher dose than Brisdelle's low-dose paroxetine.
• Escitalopram 10-20 mg reduces hot flash frequency by roughly 47% vs placebo in trials — slightly less effective than venlafaxine but with a different side effect profile.

For severe symptoms, HRT is typically more effective than any non-hormonal option. For mild-to-moderate symptoms, the gap narrows and the choice becomes more about patient preferences, contraindications, and side effect tolerability.

When each approach makes sense

HRT is the right choice when:

• You have moderate-to-severe menopausal symptoms and no contraindications.
• You also have vaginal symptoms (dryness, dyspareunia) that non-hormonal systemic treatments don't address.
• You are at risk for postmenopausal osteoporosis and could benefit from HRT's bone protection.
• You are within 10 years of menopause and under 60, where the risk-benefit for HRT is most favorable.
• You can take HRT safely based on your medical history.

Non-hormonal alternatives are the right choice when:

• You have a personal history of breast cancer or other estrogen-sensitive cancer.
• You have a history of venous thromboembolism (VTE) or stroke.
• You prefer to avoid hormone therapy for personal reasons.
• Your symptoms are primarily hot flashes without significant vaginal or bone concerns.
• You are also experiencing mood symptoms that might benefit from SSRI/SNRI treatment.

Important caveats worth knowing

• Paroxetine and tamoxifen interaction. Paroxetine (Brisdelle and other paroxetine products) can reduce the effectiveness of tamoxifen, which is used by many breast cancer survivors. This is a significant interaction and is one reason venlafaxine or escitalopram is often preferred for hot flash management in women on tamoxifen.
• SSRIs and sexual side effects. Decreased libido and anorgasmia are common SSRI side effects, and they are often unwanted in menopause patients who may already be experiencing sexual dysfunction. This is worth discussing explicitly with your provider.
• Abrupt discontinuation. SSRIs and SNRIs should not be stopped abruptly — they require a taper to avoid discontinuation symptoms. HRT can generally be stopped or tapered more flexibly.
• Vaginal symptoms need local treatment. Non-hormonal systemic treatments don't address vaginal atrophy. Women with significant vaginal dryness, dyspareunia, or recurrent urinary symptoms typically benefit from low-dose vaginal estrogen, which has minimal systemic absorption and is considered safe even for many breast cancer survivors under oncology guidance.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

Hormone Replacement Therapy (HRT)

HRT is the first-line recommendation for women with moderate-to-severe menopausal symptoms who do not have contraindications. It typically produces the largest reduction in hot flash frequency and severity — 75-90% in clinical trials — and also addresses vaginal symptoms and bone health.

Antidepressants for Vasomotor Symptoms

Antidepressants for vasomotor symptoms are appropriate for women who cannot or prefer not to use HRT. This includes women with personal history of breast cancer (for whom HRT is typically contraindicated), women with VTE history, women whose symptoms are predominantly hot flashes and not vaginal symptoms, and women who prefer a non-hormonal option. Not as effective as HRT but meaningful symptom reduction in trials.